It has been suggested that sEH inhibitors might alleviate T2DM complications by prolonging the benefits of the epoxides, with effects often being attributed to AA-derived EpETrEs based on the benefits seen with administration of exogenous epoxides [89] While the cardiovascular and renal benefits of EpETrEs are well-characterized [89], less is known about their effects on other organs. The gene discussed is EPHX2; the disease is type 2 diabetes mellitus.